Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
In this exploratory setting, cobolimab plus dostarlimab was well tolerated, with reported preliminary efficacy similar to other anti-T-cell immunoglobulin and mucin-domain containing protein-3 treatments in patients with locally advanced/metastatic melanoma. See related article by Davar et al., p. 3443.
Authors
- Theo Borgovan
- Srimoyee Ghosh
- Angela Waszak
- Kathrin Jansen (ORCID: https://orcid.org/0000-0002-3803-7680)
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Tianyun Wang
- Casilda Llácer Pérez (ORCID: https://orcid.org/0000-0002-4107-5522)
- Niranjan Yanamandra
- Brian Di Pace (ORCID: https://orcid.org/0000-0003-0568-9970)
- Antoni Ribas (ORCID: https://orcid.org/0000-0003-3669-8458)
- Arindam Dhar (ORCID: https://orcid.org/0000-0002-7929-0877)
Institutions
- University of California, Los Angeles (US)
- William Penn University (US)
- Moffitt Cancer Center (US)
- BG Medicine (United States) (US)
- Heidelberg Engineering (Germany) (DE)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Instituto de Investigación Biomédica de Málaga (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0884
- Citations
- 8
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- GlaxoSmithKline